Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients

Journal of Viral Hepatitis

Volumn 19, Issue 11, 2012, Pages 801-810

  Kosi, L ^a   Reiberger, T ^a   Payer, B A ^a   Grabmeier Pfistershammer, K ^b   Strassl, R ^a   Rieger, A ^b   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

emtricitabine; HBeAg; HBsAg loss; hepatotoxicity; lamivudine; long term treatment; tenofovir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; FEMALE; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION;

ADENINE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; DEOXYCYTIDINE; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; ORGANOPHOSPHONATES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; VIRUS REPLICATION;

EID: 84867399642     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2012.01601.x     Document Type: Article

References (30)

1. Alter MJ,. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44 (1 Suppl): S6-S9.
2. Workowski KA, Berman SM,. Sexually transmitted diseases treatment guidelines Epidemiology of viral hepatitis and HIV co-infection 2006. MMWR Recomm Rep 2006; 55 (RR-11): 1-94.
3. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22 (12): 1399-1410.
4. Peck-Radosavljevic M, Deutsch J, Ferenci P, et al. [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009]. Wien Klin Wochenschr 2010; 10: 280-302.
5. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007; 356 (25): 2614-2621.
6. Low E, Cox A, Atkins M, Nelson M,. Telbivudine has activity against HIV-1. AIDS 2009; 23 (4): 546-547.
7. De Clercq E,. Antiviral drugs in current clinical use. J Clin Virol 2004; 30 (2): 115-133.
8. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M,. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR) The CAESAR Coordinating Committee. J Infect Dis 1999; 180 (3): 607-613.
9. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45 (5): 624-632.
10. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999; 30 (5): 1302-1306.
11. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189 (7): 1185-1192.
12. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17 (1): F7-F10.
13. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40 (6): 1421-1425.
14. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43 (3): 548-555.
15. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44 (5): 1110-1116.
16. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20 (15): 1951-1954.
17. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM,. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186 (1): 23-31.
18. Den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14 (18): 2895-2902.
19. Leads from the MMWR. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. JAMA 1987; 9: 53-54.
20. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29 (2): 242-247.
21. AIDS-Clinical-Trials-Group. Table of Grading Severity of Adult Adverse Experiences. Rockville: National Institute of Allergy and Infectious Diseases, Division of AIDS, 1996.
22. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD,. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283 (1): 74-80.
23. De Vries-Sluijs TE, Reijnders JG, Hansen BE, et al. Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 2010; 139 (6): 1934-1941.
24. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140 (1): 132-143.
25. Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25 (1): 73-79.
26. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 2010; 139 (4): 1207-1217.
27. Lutgehetmann M, Volz T, Kopke A, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology 2010; 52 (1): 16-24.
28. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355 (22): 2283-2296.
29. Dore GJ, Soriano V, Rockstroh J, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS 2010; 24 (6): 857-865.
30. Lewin SR, Ribeiro RM, Avihingsanon A, et al. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. Hepatology 2009; 49 (4): 1113-1121.